Cortisol and Testosterone: HPA Axis Hyperactivation and the Pregnenolone Steal

Q: How does CRH inhibit GnRH pulsatility, and is this effect reversible with stress reduction?

CRH neurons in the hypothalamic PVN project directly to GnRH neurons in the arcuate nucleus, where CRH-R2 activation reduces GnRH pulse frequency. This is a direct synaptic inhibition, not mediated through cortisol. In acute stress models, GnRH suppression is fully reversible within 24–48 hours of stress removal. In chronic stress models, upregulation of CRH-R2 in arcuate neurons prolongs the inhibitory effect. Phosphatidylserine reduces ACTH release (and indirectly CRH signaling) but does not directly address CRH-R2 upregulation — sleep restoration and parasympathetic activation remain the most powerful reversers of GnRH suppression in chronic stress states.

Q: Is the pregnenolone steal a quantitatively significant driver of testosterone suppression in otherwise healthy men?

Yes, in conditions of chronic high-volume exercise or sustained occupational stress. In male ultraendurance athletes with chronically elevated cortisol, testosterone:cortisol ratios fall by 40–60% compared to sedentary controls, with total testosterone often in the low-normal range despite normal LH — a pattern consistent with intratesticular substrate competition rather than HPG axis failure. The steal is less quantitatively significant in moderately stressed men; in that population, CRH-mediated LH suppression is likely the dominant mechanism. Both mechanisms converge on the same intervention strategy: reducing upstream ACTH/CRH drive.

Q: What is the clinical relevance of the ashwagandha −1.16 µg/dL cortisol reduction from PMID 40746175?

A reduction of 1.16 µg/dL (~32 nmol/L) represents approximately 10–15% of morning peak cortisol (~15–20 µg/dL typical range). In men with chronic HPA hyperactivation, baseline cortisol is often 20–25 µg/dL; the absolute reduction in this population is proportionally larger. Clinically, this magnitude of cortisol reduction is associated with measurable improvements in sleep latency, recovery from exercise, and in studies with concurrent testosterone measurement, improvements in free testosterone of 10–15%. The effect is not supraphysiologic cortisol suppression — which would be therapeutically dangerous — but normalization in the direction of circadian nadir.

Q: Should phosphatidylserine and ashwagandha be dosed together, and is there redundancy?

Mechanistically, they act at distinct nodes and are additive rather than redundant. Phosphatidylserine targets pituitary ACTH secretion — upstream, acute-stress reactive. Ashwagandha withanolides target glucocorticoid receptor sensitivity and NFκB inflammatory signaling — more downstream, chronic-state modulatory. Combined, they address both the reactive HPA spike (PS) and the baseline hyperactivation from chronic inflammatory tone (ashwagandha). No direct combination RCT exists, but the mechanistic rationale for co-administration is sound and adverse interaction potential is low given distinct sites of action.

The intersection of the HPA and HPG axes is one of the most clinically consequential — and most frequently overlooked — mechanisms in male hormone physiology. Chronic HPA axis hyperactivation does not merely elevate cortisol; it systematically suppresses the HPG axis through at least three distinct molecular pathways operating in parallel: direct CRH inhibition of GnRH pulsatility, cortisol-mediated suppression of LH release at the pituitary, and competitive diversion of pregnenolone substrate from gonadal steroidogenesis toward adrenal glucocorticoid synthesis.

The result is a hormonal phenotype that presents clinically as low testosterone, low energy, high inflammation, and disrupted sleep — often misattributed to primary hypogonadism rather than functional HPA-mediated suppression. The distinction matters enormously for treatment: a man with cortisol-driven testosterone suppression will not respond optimally to exogenous testosterone without addressing the upstream driver. The endocrinological literature on HPA-HPG crosstalk is robust; the nutritional intervention literature — particularly for phosphatidylserine and ashwagandha withanolides — has reached a level of mechanistic and clinical evidence that warrants serious consideration.

CRH, ACTH, and Cortisol: The Three-Step Suppression of LH Pulsatility

Under chronic psychological or physiological stress, the hypothalamic paraventricular nucleus (PVN) increases CRH (corticotropin-releasing hormone) secretion. CRH serves a dual role: it stimulates ACTH release from anterior pituitary corticotrophs (canonical HPA axis activation), but it also directly inhibits GnRH neurons in the arcuate nucleus via CRH receptor type 2 (CRH-R2). This direct CRH→GnRH inhibition reduces the frequency and amplitude of GnRH pulses — the primary determinant of LH secretion amplitude.

Elevated glucocorticoids (cortisol) add a second layer of suppression: cortisol binds glucocorticoid receptors (GR) in both pituitary gonadotrophs and hypothalamic GnRH neurons, reducing LH pulse amplitude and frequency independent of CRH. In human studies, exogenous glucocorticoid administration reduces LH pulse amplitude by 30–50% within 24 hours. The third layer is adrenal-gonadal competition at the pregnenolone substrate level (the pregnenolone steal, addressed in the next section). The net effect of HPA hyperactivation is suppressed LH signaling at every level of the HPG axis — from hypothalamic GnRH frequency to pituitary LH amplitude to Leydig cell substrate availability.

The Pregnenolone Steal: CYP11B1 vs CYP11A1 Competition

Pregnenolone is the universal steroid precursor — the branch point from which all steroid hormones are synthesized. In the adrenal cortex, CYP11A1 converts cholesterol to pregnenolone, which then feeds either the glucocorticoid pathway (pregnenolone → 17-OH pregnenolone → 11-deoxycortisol → cortisol via CYP11B1) or the mineralocorticoid/androgen pathways. Under chronic stress, ACTH-driven upregulation of adrenal steroidogenesis increases flux through the CYP11B1 (cortisol synthesis) pathway, reducing the fraction of pregnenolone available for DHEA and androgen synthesis via the Δ5 pathway.

In Leydig cells, the same substrate competition occurs: the small amount of corticosterone synthesized locally competes with testosterone synthesis for pregnenolone. This is not a theoretical abstraction — studies in rodent models of chronic stress demonstrate 40–60% reductions in testicular testosterone output without reduction in LH levels, consistent with intratesticular substrate diversion. The PNMT (phenylethanolamine N-methyltransferase) feedback loop compounds this: cortisol induces PNMT expression in the adrenal medulla, increasing epinephrine synthesis, which further activates the HPA axis through sympathoadrenal-HPA crosstalk — a self-amplifying cycle that requires upstream intervention to break.

Phosphatidylserine: ACTH Suppression and the Exercise-Stress Model

Phosphatidylserine (PS) is a phospholipid concentrated in neuronal membranes that has demonstrated reproducible effects on HPA axis reactivity in both exercise-stress and psychological-stress models. The mechanism involves PS incorporation into pituitary corticotroph cell membranes, where it reduces ACTH secretion in response to CRH — an effect demonstrated at doses of 400–800 mg/day in multiple double-blind RCTs. PS does not suppress basal cortisol substantially; its effect is on the reactive cortisol spike following acute stress or intense exercise.

In the exercise-stress model most relevant to male athletes, a 2-week PS supplementation protocol (800 mg/day) reduced post-exercise ACTH by 25–30% and cortisol by 20% compared to placebo, without blunting the anabolic GH/IGF-1 response. This selectivity — reducing catabolic cortisol spike without suppressing anabolic signaling — is mechanistically consistent with its pituitary site of action (ACTH) rather than peripheral glucocorticoid receptor blockade. For men with chronically elevated cortisol from occupational or training stress, PS represents a well-characterized upstream intervention that targets the ACTH→cortisol step before the downstream testosterone-suppressing effects accumulate.

Ashwagandha Withanolides: HSP70/90 Interaction and GR Sensitivity Modulation

Ashwagandha (Withania somnifera) root extract KSM-66 contains withanolides — steroidal lactones including withaferin A, withanolide D, and withanolide B — that interact with heat shock proteins HSP70 and HSP90. In unstressed cells, HSP90 maintains glucocorticoid receptors (GR) in an inactive conformation; ligand binding (cortisol) dissociates HSP90, enabling GR nuclear translocation and transcription of glucocorticoid-responsive genes. Withanolides stabilize HSP70 chaperone activity and appear to modulate GR sensitivity — reducing receptor hypersensitization that characterizes chronic stress states — without producing glucocorticoid receptor blockade.

The 2025 meta-analysis (PMID 40746175) pooled data from 12 RCTs and found ashwagandha produced a cortisol reduction of −1.16 µg/dL (approximately −32 nmol/L) in the pooled cohort (95% CI significant at p < 0.001). Studies using KSM-66 at 600 mg/day demonstrated the most consistent effects. Importantly, withanolides also inhibit NFκB-mediated inflammatory signaling, reducing IL-6 and TNF-α, which independently contribute to HPA axis hyperactivation through cytokine-driven CRH secretion. The anti-inflammatory mechanism provides a second pathway by which ashwagandha interrupts the chronic stress→cortisol cycle.

The bottom line

Cortisol-driven testosterone suppression is a functional endocrine state, not a primary gonadal failure — and the distinction determines the intervention strategy. The mechanistic evidence for phosphatidylserine and ashwagandha withanolides converges on the same upstream target: reducing ACTH reactivity and glucocorticoid receptor hypersensitization before cortisol accumulates to the concentrations that suppress LH pulsatility and divert pregnenolone substrate. Helian's PM protocol positions these compounds at the evening clearance window — when cortisol should be declining and the HPG axis preparing for nocturnal testosterone synthesis — translating a molecular pathway map into a clinically rational dosing architecture.

Frequently Asked Questions

How does CRH inhibit GnRH pulsatility, and is this effect reversible with stress reduction?

CRH neurons in the hypothalamic PVN project directly to GnRH neurons in the arcuate nucleus, where CRH-R2 activation reduces GnRH pulse frequency. This is a direct synaptic inhibition, not mediated through cortisol. In acute stress models, GnRH suppression is fully reversible within 24–48 hours of stress removal. In chronic stress models, upregulation of CRH-R2 in arcuate neurons prolongs the inhibitory effect. Phosphatidylserine reduces ACTH release (and indirectly CRH signaling) but does not directly address CRH-R2 upregulation — sleep restoration and parasympathetic activation remain the most powerful reversers of GnRH suppression in chronic stress states.

Is the pregnenolone steal a quantitatively significant driver of testosterone suppression in otherwise healthy men?

Yes, in conditions of chronic high-volume exercise or sustained occupational stress. In male ultraendurance athletes with chronically elevated cortisol, testosterone:cortisol ratios fall by 40–60% compared to sedentary controls, with total testosterone often in the low-normal range despite normal LH — a pattern consistent with intratesticular substrate competition rather than HPG axis failure. The steal is less quantitatively significant in moderately stressed men; in that population, CRH-mediated LH suppression is likely the dominant mechanism. Both mechanisms converge on the same intervention strategy: reducing upstream ACTH/CRH drive.

What is the clinical relevance of the ashwagandha −1.16 µg/dL cortisol reduction from PMID 40746175?

A reduction of 1.16 µg/dL (~32 nmol/L) represents approximately 10–15% of morning peak cortisol (~15–20 µg/dL typical range). In men with chronic HPA hyperactivation, baseline cortisol is often 20–25 µg/dL; the absolute reduction in this population is proportionally larger. Clinically, this magnitude of cortisol reduction is associated with measurable improvements in sleep latency, recovery from exercise, and in studies with concurrent testosterone measurement, improvements in free testosterone of 10–15%. The effect is not supraphysiologic cortisol suppression — which would be therapeutically dangerous — but normalization in the direction of circadian nadir.

Should phosphatidylserine and ashwagandha be dosed together, and is there redundancy?

Mechanistically, they act at distinct nodes and are additive rather than redundant. Phosphatidylserine targets pituitary ACTH secretion — upstream, acute-stress reactive. Ashwagandha withanolides target glucocorticoid receptor sensitivity and NFκB inflammatory signaling — more downstream, chronic-state modulatory. Combined, they address both the reactive HPA spike (PS) and the baseline hyperactivation from chronic inflammatory tone (ashwagandha). No direct combination RCT exists, but the mechanistic rationale for co-administration is sound and adverse interaction potential is low given distinct sites of action.

Build your High Cortisol (The Burner) protocol.

Helian builds a circadian-timed supplement protocol for your exact hormonal profile — AM and PM windows, evidence-based dosages.

See your High Cortisol (The Burner) profile →

← All guides